Publications by authors named "D Holle-Lee"
Background And Objectives: Three phase 3 trials demonstrated the efficacy and safety of atogepant in episodic migraine (EM) and chronic migraine (CM) across 12-week treatment periods. This analysis evaluates improvements in efficacy and functional outcomes in the first 4 weeks of treatment with the oral calcitonin gene-related peptide receptor antagonist, atogepant, for the preventive treatment of migraine.
Methods: ADVANCE, ELEVATE, and PROGRESS were phase 3, multicenter, randomized, double-blind, placebo-controlled 12-week trials.
Article Synopsis
- Machine learning, especially Natural Language Processing, is increasingly helping to analyze unstructured health data like headache histories.
- Algorithms can effectively identify patterns and automate the diagnosis of various headache types.
- Digital tools, such as headache diaries and trigger-analysis apps, are enhancing therapy options, offering scalable non-drug treatments for headaches and migraines.*
Background: To evaluate the benefit-risk assessment of atogepant and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) vs. placebo based on the number needed to treat (NNT) and the number needed to harm (NNH) in a blended episodic migraine and chronic migraine (EM + CM) population.
Methods: The NNT was calculated based on achievement of a ≥ 50% reduction in mean monthly migraine days (MMDs) from baseline across 12 weeks.
Article Synopsis
- Atogepant is an oral medication designed to prevent chronic migraines and was tested in a study involving participants with and without medication overuse.
- The study involved 755 adults and assessed the impact of two dosages of atogepant compared to a placebo over 12 weeks, measuring changes in headache and migraine days.
- Results showed significant reductions in migraine and headache days, along with reduced medication use, particularly in participants treated with atogepant, highlighting its effectiveness in managing chronic migraines.